Dogs Read et al. (1996) used three different doses of sodium pentosan polysulfate to treat 40 geriatric dogs with well-established clinical signs of chronic
osteoarthritis (OA) with a subcutaneous injection. The 3 mg/kg dose was the most effective. In a study conducted with 10 elderly dogs with osteoarthritis given calcium pentosan polysulfate (3 mg/kg intramuscularly) once weekly for four weeks, the improvement in symptoms (seen at 1, 2, 3 and 7 weeks after initiation of therapy) was found to correlate with plasma indices of fibrinolytic activity and lipid profiles. In a study in dogs with OA secondary to cranial cruciate ligament deficiency, although no differences were identified in either functional outcome or radiographic progression using the oral calcium pentosan polysulfate compared with placebo, there were significantly lower levels of
proteoglycan breakdown products in the
synovial fluid of the osteoarthritic joints. The efficacy of subcutaneous sodium pentosan polysulfate (3 mg/kg) was tested in 40 dogs with
cranial cruciate ligament instability and found to hasten recovery, as measured by more rapidly improved
ground reaction forces, over 48 weeks.
Horses Zycosan, for horses, is a heparin-like compound and is the first injectable pentosan product to receive approval by the US
Food and Drug Administration (FDA). Zycosan is for intramuscular use in horses only and is not for use in humans. Articular cartilage fibrillation was substantially reduced by similar NaPPS treatment intramuscularly in nine horses with experimentally-induced carpal osteoarthritis. == References ==